Wegovy on the NHS for Heart Disease 2026: The NICE Cardiovascular Guidance Explained

NICE recommended Wegovy on the NHS in April 2026 for adults with established cardiovascular disease and a BMI of 27 or above.

Imagine you are in your early sixties. You had a heart attack four years ago. You take your statin and your ACE inhibitor every day without fail. Your latest BMI check came back at 28. In April 2026, you hear the news that NICE has recommended the weight-loss drug Wegovy on the NHS for people in your exact position.

The immediate questions are straightforward: do you qualify, what does the evidence actually show, how soon can you expect a GP review and what would the treatment involve in practice?

The headline is this: on 1 April 2026, NICE published final draft guidance recommending semaglutide 2.4 mg (brand name Wegovy) for adults with established cardiovascular disease and a BMI of 27 or above. Around 1.2 million people in England are expected to be eligible. NHS trusts have 90 days from the final guidance to make the treatment available, meaning the fastest trusts could be prescribing by early July 2026.

This article walks through the SELECT trial evidence, the detailed eligibility criteria, the NHS prescribing pathway, the dose schedule, the side effects and the practical steps for patients who think they may qualify.

What NICE recommended and why it matters

On 1 April 2026, NICE published final draft guidance with a clear recommendation. Semaglutide 2.4 mg, known as Wegovy, is recommended as an option for NHS use in adults with established cardiovascular disease and a body mass index (BMI) of 27 kg per square metre or above.

The specific purpose is to reduce the risk of major adverse cardiovascular events, often shortened to MACE. MACE is defined as a heart attack, stroke or death from cardiovascular causes. Established cardiovascular disease, for the purposes of this guidance, means a previous heart attack, a previous ischaemic stroke or symptomatic peripheral arterial disease.

The BMI threshold of 27 is significant. This is the overweight category, not the obesity category which starts at 30. This marks the first time NICE has recommended a GLP-1 receptor agonist medication on the NHS specifically for reducing cardiovascular risk, rather than primarily for weight loss or glycaemic control in diabetes. It represents a major expansion of access.

Prior to this, the NHS pathway for Wegovy was narrow, limited to specialist weight management services with much higher BMI thresholds. The new cardiovascular indication is separate. Around 1.2 million people in England are projected to meet the criteria. NHS trusts are expected to carry out the guidance within 90 days of its finalisation, with services anticipated to come online progressively through the summer and autumn of 2026. This is a meaningful shift in how cardiovascular risk is managed in people who are overweight but not obese.

The SELECT trial in plain terms

The evidence behind the NICE recommendation comes from the SELECT trial. SELECT was a large, multinational, randomised, double-blind, placebo-controlled phase 3 trial. It enrolled 17,604 adults who had a BMI of at least 27 and established cardiovascular disease, but did not have diabetes.

Participants were randomly assigned to receive either semaglutide 2.4 mg as a weekly subcutaneous injection or a placebo. Everyone continued with their usual cardiovascular medications, such as statins, ACE inhibitors or ARBs, antiplatelet drugs and beta blockers.

The primary outcome was the time to the first major adverse cardiovascular event (MACE). The median follow-up period was about 40 months.

The headline result was clear: semaglutide reduced the risk of first MACE by 20 percent compared with placebo. This is expressed statistically as a hazard ratio of 0.80, with a 95 percent confidence interval of 0.72 to 0.90 and a p-value of less than 0.001. This represents a clinically meaningful reduction in absolute risk.

Participants in the semaglutide group also lost an average of around 9 to 10 percent of their body weight over the trial period. Interestingly, pre-specified analyses suggested the cardiovascular benefit appeared to be at least partly independent of the amount of weight lost. This points to additional effects on underlying processes like inflammation and atherosclerosis.

The side effect profile was consistent with other GLP-1 trials, with gastrointestinal issues being the most common. The strength and clarity of the SELECT results are why NICE was able to move forward with this recommendation.

Who qualifies under the new NICE guidance

Understanding eligibility requires checking three specific criteria.

First, you must have established cardiovascular disease. This is defined as at least one of the following: a previous heart attack (myocardial infarction), a previous ischaemic stroke or symptomatic peripheral arterial disease. Peripheral arterial disease typically presents as pain in the legs when walking, known as intermittent claudication.

Second, you must have a BMI of 27 kg per square metre or above. This is the key expansion, moving below the traditional obesity threshold. Third, you must be aged 18 or over.

There are important exclusions. Patients with type 2 diabetes are not automatically excluded, but their care will typically be managed by their diabetes team under existing pathways. Patients with type 1 diabetes are not eligible under this new cardiovascular indication. The guidance is for secondary prevention, meaning you must have already had a qualifying event. People with multiple risk factors but no prior heart attack or stroke (primary prevention) do not qualify. A previous haemorrhagic stroke alone, without other qualifying disease, also does not meet the criteria.

There are absolute contraindications, including pregnancy, breastfeeding, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A history of severe pancreatitis or severe gastroparesis requires careful specialist assessment.

The 1.2 million figure is a population-level estimate. Individual eligibility must always be confirmed by a clinician reviewing your specific medical history.

How the NHS rollout works and how to access it

The practical pathway for accessing Wegovy under the new guidance will unfold over 2026. NHS trusts have 90 days from the finalisation of the NICE guidance to establish services. The earliest adopters could be prescribing by early July 2026, with most trusts expected to have systems in place by the autumn.

The primary route will be through secondary care specialists. If you have established cardiovascular disease, you likely already have reviews with either your GP or a hospital-based cardiology, stroke or vascular clinic.

The first step is to book a GP appointment to discuss your potential eligibility. It is helpful to bring a summary of your medical history, including details of your cardiovascular event, your current medication list and your most recent BMI, blood pressure and cholesterol results.

If your GP agrees you are likely eligible, the next step is a referral to a local cardiology, stroke or vascular service. The prescribing decision will be made by a specialist in these fields or by a specialist GP operating under a shared-care protocol. You cannot self-refer for this treatment.

Once prescribed, the treatment starts at a low dose and increases gradually. The standard schedule is 0.25 mg weekly for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg and finally the 2.4 mg maintenance dose. Each step lasts four weeks, so the full dose escalation takes 16 to 20 weeks.

Ongoing reviews will occur at three months, six months and then annually. It is important that you do not stop taking your statins, blood pressure tablets or other heart medications when starting Wegovy. The trial benefit was achieved on top of this standard care.

Side effects, safety and the MHRA black triangle

Like all medications, semaglutide 2.4 mg has potential side effects. The most common are gastrointestinal. These include nausea, vomiting, diarrhoea, constipation, abdominal pain, indigestion and fatigue. These effects are usually most pronounced during the first 8 to 12 weeks as the dose is being increased. For most people, they settle down with time.

Practical steps like eating smaller, slower meals and avoiding rich or sugary foods can help manage them. If side effects are troublesome, a prescriber may choose to pause the dose escalation or step back down to a lower dose. In the SELECT trial, around 1 in 10 participants stopped treatment due to side effects.

Less common but more serious side effects include gallstones and inflammation of the gallbladder, which occurred in around 2 to 3 percent of trial participants. A rare but serious risk is acute pancreatitis. You should seek urgent medical attention if you develop persistent, severe upper abdominal pain while taking Wegovy. Severe gastroparesis or delayed stomach emptying can also occur in those with existing digestive issues.

As a new medicine under close monitoring, Wegovy is part of the MHRA black triangle scheme. This means any suspected adverse event should be reported through the official Yellow Card scheme.

There are important contraindications, including pregnancy, breastfeeding and a personal or family history of specific thyroid cancers. Semaglutide slows stomach emptying, which can affect the absorption of other oral medicines. Patients on drugs like warfarin, levothyroxine or oral contraceptives should have their treatment reviewed by their prescriber.

To help maintain muscle mass during weight loss, incorporating resistance exercise and ensuring adequate protein intake is sensible advice.

How the new cardiovascular indication differs from the obesity pathway

Two separate NHS pathways for Wegovy now exist side by side.

The original obesity pathway, established in 2023, remains unchanged and is restricted. It requires a referral to a specialist tier 3 weight management service, a BMI of 35 plus at least one obesity-related comorbidity or a BMI of 40, and treatment is typically limited to a maximum of two years. Waiting lists for these services are often long.

The new cardiovascular pathway, from April 2026, is entirely different. It runs through cardiology, stroke and vascular services, not weight management clinics. The eligibility criteria are distinct: a BMI of 27 plus established cardiovascular disease. There is no fixed two-year treatment limit under this indication, as the goal is long-term reduction of cardiovascular risk.

A patient with a high BMI and a previous heart attack might technically be eligible for both pathways. In practice, they will likely access treatment through the cardiovascular route because it is expected to be quicker and does not have a strict time constraint. The two systems may integrate in the future, but for now they operate separately.

If you are already paying for Wegovy privately and believe you now qualify under the cardiovascular criteria, do not stop your private prescription abruptly. Instead, speak to your GP about an eligibility review. The aim should be an orderly transition to NHS care without a gap in treatment, as stopping suddenly can lead to weight regain and a potential rebound in cardiovascular risk factors.

What to do if you think you might qualify

If the news has prompted you to consider your own eligibility, a calm, step-by-step approach is best.

First, privately review the core criteria: established cardiovascular disease (previous heart attack, ischaemic stroke or symptomatic PAD), a BMI of 27 or above and age 18 plus. If you do not meet all three, you are not eligible under this new guidance.

Second, book a routine GP appointment. State clearly that you wish to discuss potential eligibility for Wegovy under the new April 2026 NICE cardiovascular guidance. Having your medical summary, medication list and recent health metrics to hand will make the consultation more efficient.

Third, be prepared for a possible referral to a hospital specialist for the final prescribing decision. Lead times will vary between different NHS trusts as they set up their services over the coming months.

Fourth, while waiting, do not source Wegovy from unlicensed websites. The MHRA regularly issues warnings about counterfeit weight-loss injections. UK-regulated online pharmacies like Boots, Superdrug, Pharmacy2U, LloydsPharmacy and Asda Online Doctor are options for legal private supply if you choose not to wait.

Fifth, continue all your prescribed heart and circulation medicines. Finally, use the waiting period to build healthy habits. Prioritise protein in your diet, aim for two sessions of strength-building exercise per week, walk daily and moderate your alcohol intake. These behaviours support better outcomes alongside medication.

Frequently Asked Questions

What did NICE recommend on Wegovy in April 2026

On 1 April 2026, NICE published final draft guidance recommending semaglutide 2.4 mg (Wegovy) on the NHS for adults with established cardiovascular disease and a body mass index of 27 kg per square metre or above, to reduce the risk of major adverse cardiovascular events (heart attack, stroke or cardiovascular death). Around 1.2 million people in England are expected to qualify. NHS trusts have 90 days to make it available, so early July 2026 in the fastest trusts.

Who counts as having established cardiovascular disease

Under the NICE definition, established cardiovascular disease means at least one of the following: a previous heart attack (myocardial infarction), a previous ischaemic stroke or symptomatic peripheral arterial disease (typically intermittent claudication on walking, sometimes critical limb ischaemia). A previous haemorrhagic stroke alone or risk factors without an event (primary prevention) do not qualify under the new guidance. Patients with multiple cardiovascular risk factors but no qualifying event may still benefit from existing NHS prevention pathways.

What did the SELECT trial actually show

SELECT was a multinational randomised, double-blind, placebo-controlled phase 3 trial of 17,604 adults with a BMI of at least 27 and established cardiovascular disease, no diabetes. Over a median 40 months, semaglutide 2.4 mg weekly reduced first major adverse cardiovascular events by 20 percent compared with placebo (hazard ratio 0.80, p less than 0.001). Mean weight loss was around 9 to 10 percent. The cardiovascular benefit appeared independent of weight loss, suggesting effects on inflammation and atherosclerosis as well.

How is the NHS rollout going to work

NHS trusts have 90 days from final NICE guidance to make Wegovy available for the new cardiovascular indication. The earliest fast-moving trusts should be prescribing by early July 2026 and most will be live by autumn 2026. The pathway will run primarily through cardiology, stroke and vascular services, with some trusts using specialist GP shared-care models. Ask your GP for a review if you think you qualify. Patients cannot self-refer.

What dose is involved and how long does treatment take to ramp up

Wegovy starts at 0.25 mg subcutaneous weekly for 4 weeks, then increases to 0.5 mg, 1.0 mg, 1.7 mg and finally the maintenance dose of 2.4 mg weekly. Each step is held for 4 weeks. Full titration takes 16 to 20 weeks. The slow ramp is to manage gastrointestinal side effects, which are most pronounced during dose increases. The 2.4 mg maintenance dose is the dose with cardiovascular evidence from the SELECT trial.

What side effects should I expect

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, abdominal pain, indigestion and fatigue. They are worst in the first 8 to 12 weeks during dose escalation and usually settle. Less common: gallstones and gallbladder inflammation (around 2 to 3 percent of trial participants). Rare: acute pancreatitis. Wegovy is under the MHRA black triangle scheme so any adverse event should be reported via the Yellow Card scheme.

I am on private Wegovy already. Should I switch to the NHS

If you think you qualify under the new cardiovascular indication, ask your GP for a review. Do not stop your private prescription before the NHS pathway is confirmed and a transition plan is agreed, because stopping a GLP-1 abruptly is associated with weight regain and possible rebound in cardiovascular risk. Once the NHS prescription is in place, arrange an orderly switch with no gap. Boots, Superdrug, Pharmacy2U, LloydsPharmacy and Asda Online Doctor remain regulated UK options if you prefer private continuity.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.